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Purpose: Smooth muscle cell (SMC) migration contributes ignificantly to the hyperplas- 
tic response that follows arterial injury. In vitro studies have shown that a number of  
growth factors and extracellular matrix (ECM) proteins individually stimulate vascular 
SMC migration. However, after arterial injury, SMCs exist in a complex environment in
which they are exposed to many of these proteins imultaneously. The response of SMCs 
to multiple simultaneous stimuli may differ significantly from their response to any single 
individual stimulus. In this study, we evaluated the chemotactic response of  human 
vascular SMCs to various combinations of  growth factors and ECM proteins. 
Methods: Human saphenous vein SMCs were used for all experiments. Using a 4-hour 
modified Boyden-chamber assay, we evaluated the effect on SMC chemotaxis of  combi- 
nations of  one of  three growth factors (platelet-derived growth factor [PDGF]-AB, basic 
fibroblast growth factor [bFGF], or epidermal growth factor [EGF]), and one of four 
ECM proteins (fibronectin, laminin, or collagen type I or IV). A standard fluorimetric 
assay was used to assess changes in intracellular calcium ([CaZ+]i) in response to the 
various combinations of  growth factors and ECM proteins. 
Results: A simple additive effect was seen between ECM proteins and bFGF or EGF. 
However, when SMCs were simultaneously exposed to PDGF and ECM proteins, we 
observed a synergistic ncrease in chemotaxis. This synergy was evident for all concentrations 
of  collagen type I and IV but only with higher concentrations offibronectin and laminin. We 
evaluated whether intracellular calcium may be the signaling pathway through which this 
synergistic effect is mediated. Although ECM proteins alone did not stimulate a rise in 
[Ca2+]i, ECM proteins emhanced the early peak in [Ca2+]i induced by PDGF. 
Conclusion: These data show that PDGF acts synergistically with the ECM proteins to 
promote SMC migration; this effect appears to be specific for PDGF and was not 
observed with other growth factors. The mechanism responsible for this phenomenon 
may be a synergistic increase in [Ca2+]i in SMCs simultaneously exposed to both 
proteins. (J Vasc Surg 1997;26:104-12.) 
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The long-term patency of  vascular econstructions 
is limited by restenosis and eventual graft failure that 
occurs in up to 20% to 30% of  patients. 1,2 A hyper- 
plastic intimal process, which involves smooth mus- 
cle cell (SMC) migration, proliferation, and the pro- 
duction of  extracellular matrix (ECM), is responsible 
for restenosis. 3 Critical for the initiation of  this pro- 
cess is the migration of  vascular SMCs from the 
arterial media to the intima. 4 
In response to arterial injury, SMCs are stimu- 
lated to migrate by a number  of  different factors that 
are present within the arterial walk s Platelet-derived 
growth factor (PDGF) is considered to be the proto- 
typical agonist o f  SMC migration. However, this 
laboratory has recently shown that ECM proteins 
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such as fibronectin, laminin, and collagen types I and 
IV are also potent agonists of human vascular SMC 
chemotaxis. 6 Moreover, the chemotactic effect of 
many of these ECM proteins is more profound than 
that of growth factors uch as PDGF, basic fibroblast 
growth factor (bFGF), or epidermal growth factor 
(EGF). 
Although the influence of individual growth fac- 
tors and ECM proteins on SMC migration has been 
investigated, the effect of combinations of these fac- 
tors on cellular locomotion has not. Early after an 
arterial injury, SMC are simultaneously confronted 
with a multitude of growth factors and ECM pro- 
teins, many of which have the potential to influence 
SMC migration. The response of the medial SMC is 
presumably a composite of the effects of the individ- 
ual agonists. However, these multiple stimuli may 
interact in several ways. The migratory response to 
one factor could mask that of a second factor, with 
the combined response being equivalent only to that 
of the more potent agonist. Alternatively, the effects 
of two stimuli could be additive. The two proteins 
may also interact in a synergistic manner, with the 
effect of the combination of proteins on migration 
being greater than the sum of their individual effects. 
The focus of this study was to evaluate the conse- 
quence of combining agonists of SMC migration. To 
this end, we chose three growth factors that are 
released at the time of arterial injury and four ECM 
proteins that are also prominent within the arterial 
wall. Our goal was to determine the individual effects 
of these proteins on SMC chemotaxis and then to 
compare these effects with the chemotactic response 
produced by combinations of growth factors and 
ECM proteins. In addition, we hoped to elucidate a
mechanism that would explain potential synergism, if 
any, that exists between PDGF and ECM proteins by 
evaluating the effect of these agonists on intracellular 
messengers. We have previously shown a rise in intra- 
cellular calcium ([Ca2+]i) to be necessary for SMC 
migration in response to PDGF alone, 7therefore we 
postulated that alterations in [Ca 2+ ]i may contribute 
to physiologic interactions between ECM and 
growth factors. 
MATERIAL AND METHODS 
Materials. Human recombinant PDGF-AB was 
obtained from Upstate Biotechnologies Inc. (Lake 
Placid, N.Y.). Bovine flbronectin, Engelbreth-Holm- 
Swarm mouse sarcoma laminin, calf skin collagen 
I, human placental collagen IV, digitonin, ethylene- 
glycol-bis-(S-amino-ethyl ether)N,N'-tetraacetic acid 
(EGTA), and the smooth muscle-specific a tin immu- 
nostaining ldt were obtained from Sigma Chemical Co. 
(St. Louis, Mo.). Fura-2-acetoxymethyl ester was ob- 
tained from Molecular Probes, Inc. (Eugene, Ore.). 
~-Glutamine was obtained from BioWhitaker (Walkers- 
ville, Md.). Dulbecco's Modified Eagle's Medium 
(DMEM), phosphate buffered saline (PBS), fetal bo- 
vine serum, trypsin-ethylenediaminetetraacetic id 
(EDTA), penicillin-streptomycin-fungizone s lution, 
and N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic 
acid (HEPES) were obtained from GIBCO BRL Life 
Technologies (Galthersburg, Md.). Polycarbonate 8 
b~m-pore membranes were from Poretics Corp. (Liver- 
more, Calif.). 
Cell culture. Human SMCs were explanted 
from saphenous veins harvested at the time of aorto- 
coronary or peripheral arterial bypass grafting as pre- 
viously described. 6,8 Endothelial and adventitial lay- 
ers were gently removed from segments of vein, and 
fragments of the medial ayer were placed onto tissue 
culture plates. Outward-growing SMCs were har- 
vested and subcultured in DMEM supplemented 
with 10% fetal bovine serum, 25 mmol /L  HEPES, 
40 U /ml  penicillin G, 40 btg/ml streptomycin, 100 
ng/ml  amphotericin B, and 4.8 mmol /L  L-glu- 
tamine at 37 ° C and 5% carbon dioxide in room air. 
Cells in passages 1 through 5 were used for all exper- 
imentation. SMC identity was verified by immuno- 
staining with anti-human a-actin antibody and by a 
characteristic hill-and-valley growth pattern. 
Measurement of  chemotaxis. Modified Boy- 
den-chamber migration assays were performed as de- 
scribed previously. 6 In preparation for the assay, 
SMCs were grown to confluence and then made 
quiescent in serum-free DMEM for 72 hours. Cells 
were washed in PBS, harvested with use of 0.05% 
trypsin-EDTA, and resuspended in serum-free 
DMEM. Migration was assayed for 4 hours at 37 ° C 
in a 48-well microchemotaxis chamber (Neuro- 
probe, Cabin John, Md.), with upper and lower wells 
separated by polycarbonate 8 b~m pore membranes. 
For all assays, SMCs were seeded at a density of 
50,000/well (6000/mm 2) into the upper wells of 
the chamber. The appropriate soluble agonists di- 
luted in DMEM were added to the lower wells. 
Growth factor, laminin, and flbronectin stocks were 
dissolved in aqueous olution, and the collagens were 
solubilized in dilute acetic acid. The appropriate ve- 
hicle in DMEM served as a control for each. 
Selection of the concentrations of growth factors 
and ECM proteins used for these experiments was 
based on our previous studies in which extensive 
concentration-response curves for the individual 
agonists were performed. 6 8 For all assays, we used 
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Table 1. The individual effect of growth 
factors and ECM proteins on 
SMC chemotaxis 
Agonist Chemotaxis 
(concentration) (fold increase + SD) 
PDGF-AB (1 ng/ml} 1.70 -+ 0.60 
PDGF-AB (5 ng/ml)* 4.66 -+ 0.501- 
EGF (10 ng/ml) 1.29 _+ 0.15 
EGF (100 ng/ml)* 1.61 + 0.131- 
bFGF (1 ng/ml) 0.97 _+ 0.11 
bFGF (10 ng/mi) 1.06 _+ 0.17 
Laminin (1 ~tg/ml) 1.55 -+ 0.03~ 
Laminin (20 ~tg/ml)* 3.95 -+ 0.05~ 
Fibronectin (1 vg/ml) 2.43 -+ 0.23 t
Fibronectin (20 ~tg/ml)* 5.70 _+ 0.161 
Collagen I (1 ~tg/mi)* 11.83 +_ 0.321" 
Collagen I (20 ~tg/ml) 11.57 + 0.321" 
ColIagen IV (1 i~g/ml)* 12.43 + 0.331" 
Collagen IV (20 ~tg/ml) 10.80 + 0.21~ 
ECM, Extracellular matrix; SMC, smooth muscle cell; PDGF, 
platelet-derived growth factor; EGF, epidermal growth factor; 
bFGF, basic fibroblast growth factor. 
*Concentration resulting in maximal migration. 
I"P < 0.05 for agonist versus control. 
concentrations that produced maximal stimulation 
of SMC chemotaxis and concentrations that pro- 
duced a lesser esponse (Table I). 
Upon completion of  the chemotactic assay, 
membranes were fixed in 70% ethyl alcohol at -20 ° C 
for 20 minutes and stained in hematoxylin overnight. 
The upper side of the membrane was then examined 
for cell attachment and scraped with a cotton swab, 
being careful not to disturb the cells that had mi- 
grated. The membrane was then mounted onto a 
microscope slide, and migration in each well was 
assessed with light microscopy by counting the num- 
ber of cells in five independent, random high-power 
fields at ×200 magnification. The stimulatory effect 
of the various agonists was expressed as a fold in- 
crease in migration _+ SD compared with appropriate 
control samples. 
Measurement of  [Ca2+]i. Confluent SMCs 
were washed twice with PBS and then gently har- 
vested with 0.01% trypsin/EDTA (1:5 dilution of 
commercial stock). 9 Detached cells were resus- 
pended in DMEM and centrifuged at 1000 rpm for 5 
minutes. The collected cells were then resuspended 
in an assay buffer (20 mmol /L  HEPES [pH 7.4], 
130 mmol /L  sodium chloride, 5 mmol /L  potassium 
chloride, 1 mmol /L  magnesium chloride, 1.5 
mmol /L  calcium chloride, 0.1% [wt/vol] bovine 
serum albumin, and 10 mmol /L  glucose) l° that 
contained 2 ~tmol/L fura-2-acetoxymethyl ester and 
incubated at 37 ° C for 30 minutes. The cells were 
again centrifuged and washed and resuspended in an 
assay buffer without fura-2-acetoxymethyl ester for a 
final concentration of 1 X 10 6 cells/ml. 
Cells were placed into plastic cuvettes with use of 
2 × 106 cells per measurement, suspended with a 
magnetic stir bar, and maintained at 37 ° C. Agonists 
were added at the beginning of each measurement 
to attain the final concentrations as indicated. 
Fluorescence was measured with a temperature-con- 
trolled, dual-excitation wavelength spectrofluorom- 
eter (SPEX Fluorolog-2, Edison, N.J.), with excita- 
tions of 340 and 380 nm and emission of 505 nm as 
described previously) 1 The experiments were indi- 
vidually calibrated with the addition of 40 txmol/L 
digitonin and 20 mmol /L  EGTA. [Ca2+]i was then 
calculated from the corrected fluorescence ratios as 
described by Gr3Tnkiewicz et al., 12 and displayed 
graphically with use of SPEX DM3000 software. 
Calculation o f  additive effect o f  growth fac- 
to r -ECM protein combinations and statistical 
analysis. The theoretical or expected additive ffect 
of combinations of growth factors and ECM proteins 
was calculated by simply adding together the individ- 
ual effects of these factors. Individual experiments 
were conducted in triplicate for each cell line. To add 
the individual results from two different factors in a 
manner that allowed calculation of an average and an 
SD, all possible combinations of each of  the individ- 
ual triplicate results from each factor were added 
together; the result was 9 data points. We then cal- 
culated the mean _+ SD of these 9 data points and 
considered this to be the theoretical or expected 
additive ffect. This result was then statistically com- 
pared with the mean _+ SD of the actual chemotaxis 
observed when SMCs were assayed in the presence of 
both chemoattractants simultaneously. Statistical 
comparisons were made by means of an unpaired 
Student test with Statview (BrainPower Inc., Cala- 
basas, Calif.) software on a Macintosh System (Apple 
Computer, Inc., Cupertino, Calif.). For all compari- 
sons, a p value of less than 0.05 was considered to be 
significant. The reported results are a representative 
example from one cell line; however, we confirmed 
these observations using three cell lines from differ- 
ent donors. 
RESULTS 
Chemotaxis to individual growth factors and 
ECM proteins. Initial experiments were designed 
to evaluate the individual influence on SMC migra- 
tion of three growth factors (PDGF-AB, EGF, and 
bFGF) and four ECM proteins (collagen types I and 
IV, fibronectin, and laminin; Table I). Both PDGF 
and EGF produced a concentration-dependent h~- 
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Fig. 1. Smooth muscle cell (SMC) chemotaxis in response to combinations ofplatelet-derived 
growth factor (PDGF) and extracellular matrix (ECM) proteins. SMC chemotaxis was mea- 
sured in response to PDGF: laminin (LM; A), fibronectin (FN; B), collagen I (CN I; C), 
collagen IV (CN IV," D), or combinations ofthese factors in the concentrations indicated. The 
calculated additive effect, derived as described in the Material and Methods section from the 
individual responses (open bars), is compared with chemotaxis that results.from coincubating SMCs 
simultaneously with PDGF and ECM proteins (solid bars). Results are expressed as fold increase _+ 
SD compared with migration ofunstimulated control. Experiments were performed intriplicate and 
repeated with use of at least three cell lines from different donors. Data from a representative 
experiment are shown. *p < 0.05, coincubation versus calculated additive ffect. 
crease in SMC chemotaxis, whereas bFGF did not 
stimulate SMC chemotaxis at any concentration. The 
chemotactic effect of collagen I and IV was equal and 
significantly greater than that offibronectin or laminin. 
The combined effect o f  growth factors and 
ECM proteins on SMC chemotaxis. To evaluate 
the effect on SMC chemotaxis of combinations of 
growth factors and ECM proteins, we first calculated 
the expected additive effect by summing the effect of 
the individual factors as described in the Material and 
Methods section. This value was then compared with 
the actual chemotactic response found when SMCs 
were simultaneously stimulated with growth factor- 
ECM protein combinations. 
Synergism was found between PDGF and all four 
of the ECM proteins. The findings with collagen 
types I and IV were similar. PDGF interacted with 
both low (1 txg/ml) and high (20 txg/ml) concen- 
trations of collagen in a synergistic manner to pro- 
duce a chemotactic response that was consistently 
20% to 60% above that expected by the addition of 
the individual effects of these proteins (Fig. 1). The 
findings with fibronectin and laminin were slightly 
different han that of the collagens. Stimulating with 
PDGF and low concentrations ( I  ~xg/ml) of fi- 
bronectin and laminin produced a response that was 
no different than the addition of the individual 
responses. However, synergy was observed when 
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Fig. 2. SMC chemotaxis in response to combinations ofepidermal growth factor (EGF) and 
(ECM) proteins. SMC chemotaxis was measured in response to EGF: LM (A), FN (B), CN I 
(C), CN IV (D), or combinations of these factors in the concentrations indicated. The 
calculated additive ffect, derived as described in the Material and Methods section from the 
individual responses (open bars), is compared with chemotaxis that results from coincubating 
SMC simultaneously with EGF and ECM proteins (solid bars). Results are expressed as fold 
increase _+ SD compared with migration ofunstimulated control. Experiments were performed 
in triplicate and repeated with use of at least hree cell lines from different donors. Data from a 
representative experiment are shown. *p < 0.05, coincubation versus calculated additive effect. 
PDGF was combined with higher concentrations (20 
txg/ml) of either of these proteins (Fig. 1). For 
PDGF (5 ng/ml )  and laminin or fibronectin (20 
txg/ml), this rcsponsc was 43% to 70% greater than 
that calculated by the addition of the individual ef- 
fects of  these proteins. 
We next evaluated the cffect on chemotaxis of 
simultaneously exposing SMCs to ECM proteins and 
EGF. We found that when SMCs were simulta- 
ncously exposed to any of the four ECM proteins 
and EGF, the resultant effect was equivalent to that 
calculated by the addition of the individual effects of 
both factors (Fig. 2). Thus, synergy was not observed 
with any EGF-ECM protein combination. 
bFGF alone did not stimulate SMC chcmotaxis. 
We have consistently made this observation i human 
saphenous vein SMCs, in contrast to our findings in rat 
aortic SMCs in which bFGF does have a chemotactic 
effect (unpublished observations). We postulated that, 
despite the lack of an individual effect on SMC chemo- 
taxis, bFGF may augment the chemotactic effect of the 
various ECM proteins. However, we found that the 
chemotactic responses from combinations ofbFGF and 
ECM proteins were identical to the responses from 
ECM proteins alone (data not shown). 
The individual and combined effect o f  growth 
factors and ECM proteins on levels o f  [Ca2+]i. 
In an attempt o find a mechanism that would ex- 
plain the synergism between PDGF and ECM pro- 
teins, we explored the effect of individual growth 
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factors and ECM proteins, as well as their combina- 
tions on levels of [Ca2+]i. We chose to study [Ca2+]i 
because of previous work in this laboratory that 
showed that a rise in [Ca2+]i s required for PDGF- 
induced SMC migration. 7 We hypothesized that 
PDGF and ECM proteins may produce arise [Ca2+]i 
that was greater than their individual independent 
effects. 
[Ca2+]i was measured in SMCs exposed to PDGF 
(5 ng/ml)  and the four ECM proteins (20 ~tg/ml). 
SMCs stimulated with PDGF exhibited a [Ca2+]i 
response that included an initial peak lasting approx- 
imately 3 minutes, followed by a plateau above basal 
levels that persisted for several minutes (Fig. 3). 
None of the ECM proteins produced significant al- 
terations in [Ca2+]i (Fig. 3), even with continuous 
measurement for up to 30 minutes. When any one of 
the four ECM proteins was added in combination with 
PDGF, there was a consistent increase in the magnitude 
of the early peal; in [Ca2+]i above that observed with 
PDGF alone. This increase ranged from 40% for colla- 
gen I to 55% for collagen IV. The duration of the initial 
peal; was also consistently greater ha SMCs exposed to 
ECM protein-PDGF combinations. However, simul- 
taneous exposure of SMCs to ECM proteins and 
PDGF did not effect he duration or magnitude of the 
plateau in [Ca2+]i (Fig. 3). 
DISCUSSION 
After the injury that accompanies vascular econ- 
struction, SMCs are exposed to and influenced by 
growth factors, ECM proteins, cytokines, and other 
inflammatory mediators. These factors are derived 
from the arterial wall or from circulating blood cells 
such as platelets, monocytes, and leukocytes, or they 
are secreted by endothelial cells or SMCs themselves. 
Although the effect of many of these individual fac- 
tors on SMC migration has been evaluated, the be- 
havior of  an SMC concurrently exposed to both 
growth factors and ECM proteins has not been stud- 
ied. Because growth factors and ECM proteins me- 
diate their effects through different receptors and 
signaling pathways, their combined influence on 
SMC chemotaxis i not predictable and is presum- 
ably dependent on the point of intersection of these 
pathways. We have shown previously that a series of 
growth factors and ECM proteins are chemotactic 
for human saphenous vein SMCs. 6 In the present 
study we have extended these investigations by eval- 
uating the chemotactic response of SMCs to combi- 
nations of growth factors and ECM proteins. 
We found that although both PDGF and ECM 
proteins alone provide a significant stimulus for SMC 
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Fig. 3. Measurement ofintracellular calcium ([Ca2+]i) in 
response to PDGF and ECM proteins. Quiescent human 
SMCs were loaded with 2 ~mol/L fura-2-acetoxymethyl 
ester and stimulated with either PDGF-AB (5 ng/ml) 
alone (broken lines), ECM proteins alone (dotted lines) 
[LM (A), FN (B), CN I (C), or CN IV (D)] or with 
combinations of PDGF and ECM proteins (solid lines). 
[Ca2+]i was detected by fluorimetry as described in the 
Material and Methods section. Experiments were per- 
formed in at least three cell lines from different donors. 
Curves from a representative experiment are shown. 
migration, simultaneous exposure of SMCs to both 
factors results in more chemotaxis than would be 
anticipated by adding the individual effects of these 
agonists. Thus PDGF and all four ECM proteins 
tested act in a synergistic fashion to stimulate SMC 
migration. For collagen types I and IV, this effect was 
evident for both high- and low-protein concen- 
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trations. For fibronectin and laminin, synergy was 
observed between PDGF and only higher concentra- 
tions (20 ~g/ml) of ECM protein. Intrigued by 
these findings, we then evaluated whether a similar 
synergistic response might be found when ECM pro- 
teins were combined with other growth factors. 
However, asynergistic hemotactic response was not 
observed in SMCs stimulated by ECM proteins and 
either EGF or bFGF. 
Synergism between growth factors and ECM 
proteins has been shown in other cell types. In the 
human breast cancer cell line MCF-7, chemotaxis 
induced by insulin-like growth factor I was found to 
be enhanced by either vitronectin or type IV colla- 
gen. Enhancement of the effect of insulin-like 
growth factor I by vitronectin was mediated by the 
~v[3~ integrin and the e~2131 integrin was responsible 
for the observed synergy between i sulin-like growth 
factor I and collagen. 13 Yabkowitz et al) 4 showed 
that thrombospondin synergistically potentiates 
PDGF-dependent migration of calf pulmonary artery 
SMCs. SMC migration in response to PDGF was 
enhanced nearly 60% in the presence of concentra- 
tions ofthrombospondin that alone had no effect on 
SMC migration. 
The mechanism ofthe synergistic effect of PDGF 
and ECM proteins on SMC chemotaxis i  not clear. 
Growth factors initiate their effect by binding to cell 
surface receptors, which in turn activate intracellular 
signaling pathways. These second-messenger path- 
ways then communicate with the cytoskeletal net- 
work of the cell and migration ensues. ECM proteins 
alter cellular behavior by binding to integrin recep- 
tors, which are dimeric proteins composed of alpha 
and beta subunits) S Integrins can directly alter the 
cytoskeleton by interacting with a series of proteins 
that bridge the integrin and actin filaments (the focal 
adhesion complex). 16 Alternatively, integrins, like 
growth factor eceptors, can mediate cytoskeletal re- 
organization by activating a series of signaling path- 
ways. Thus, if ECM proteins and growth factors 
interact to synergistically augment SMC chemotaxis, 
this enhancement must occur at either the receptor 
level or at a mutual or intersecting downstream sig- 
naling pathway. 
We have previously shown that alterations in 
[Ca2+]i are necessary for growth factors induced 
SMC migration. 7 PDGF consistently produces an 
immediate rise in [Ca2+]i that peaks at 60 seconds. 
[Ca2+]i then remains persistently elevated at a level 
that is approximately 40% of this peak. We postulated 
that [Ca2+]i might be the point of juncture between 
the signaling pathways that mediate ECM protein 
and PDGF-induced chemotaxis. Interestingly, we 
found that stimulating SMCs with soluble forms of 
any of the four ECM proteins did not produce arise 
in [Ca2+]i . Despite the lack of a [Ca2+]i response to 
ECM proteins, we considered the possibility that 
ECM proteins might augment the rise in [Ca2+]i 
produced by PDGF. Accordingly, we measured 
changes in [Ca2+]i n response to combinations of 
ECM proteins and growth factors. We were able to 
repeatedly show augmentation f the early peak in 
[Ca2+]i produced by PDGF by all four ECM pro- 
teins (Fig. 3). 
The sequence of signals that leads to the early 
peak in [Ca2+]i nduced by PDGF is well established. 
Ligand binding to the PDGF receptor activates 
phospholipase CT, which in turn catalyzes the hydro- 
lysis ofphosphatidylinositol 4,5-bisphosphate to ino- 
sitol trisphosphate and diacylglycerol. 16,17 Inositol 
trisphosphate then stimulates the release of [Ca2+]i 
stores from the sarcoplasmic reticulum. Although the 
signaling pathways activated by integrin receptors are 
only now being defined, there is increasing evidence 
that ECM proteins can alter turnover of phospho- 
lipid messengers. It has been shown in fibroblasts 
that fibronectin can increase the production ofphos- 
phatidylinositol 4,5-bisphosphate nd its subsequent 
hydrolysis and formation ofinositol trisphosphate} s 
Although we did not observe an overt rise in SMC 
[Ca2+]i in response to soluble ECM proteins, an 
ECM protein-induced increase in the production of 
could contribute to the augmentation in the early 
release of [Ca 2+ ]i that we observed when SMCs were 
coincubated with PDGF and ECM proteins. 
It is unlikely that augmentation in the early peak 
in [Ca2+]i is the sole mechanism for the synergistic 
interaction of PDGF and ECM proteins. In our pre- 
vious studies with PDGF, it appeared that he plateau 
or later elevation in [Ca2+]i was more critical for 
SMC migration than the early peak. 7 When SMCs 
were coincubated with ECM proteins and PDGF, 
the height and duration of the [Ca2+]i plateau was 
identical for the PDGF-ECM protein combination 
and PDGF alone. Migration is a complex process 
that involves a multitude of signaling pathways and 
protein cytoskeletal interactions. It would be unreal- 
istic to assume that the pathways for integrin- and 
growth factor-induced migration intersect at only 
one level. 
Synergism between ECM proteins and PDGF 
may also be the result of interactions atthe receptor 
level. There is evidence that ECM proteins or their 
associated integrins can up- or down-regulate 
growth factor eceptors. In murine osteoblastic cells, 
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activation of the a2131 integrin by collagen resulted in 
decrcased expression of the gene for the transform- 
ing growth factor 13-receptor, with a resultant de- 
crease in the number of cell surface receptors. 19Re- 
cent studies by Bartfeld et al.,20 and others 2~ provide 
evidence that there may be "crosstalk" between 
growth factor receptors and integrins. Tyrosine 
phosphorylation bythe PDGF receptor of the cyto- 
plasmic domain of integrin receptors, or of proteins 
associated with the focal adhesion complex, has been 
shown to modulate the function of these integrin 
receptors and their avidity for matrix components. 
Further studies will be rcqnired in our human SMC 
model to determine whether modulation of cell sur- 
face receptors can explain the synergistic effects of 
PDGF and ECM proteins on cellular motility. 
Matrix proteins can exist in both solublc and 
insoluble forms that vary in their propensity to stim- 
ulate migration. We have recently shown that di- 
rected motility to insoluble substrate-bound proteins 
(haptotaxis) is a more potent stimulus of SMC move- 
ment han directcd migration to soluble factors (che- 
motaxis) .6It is difficult o estimate the relative in vivo 
effect of these two stimuli on SMC migration after 
arterial injury. In these experiments, we have as- 
sumed that soluble matrix proteins are of greatest 
importance. Our data reveal synergy between PDGF 
and soluble ECM proteins in their ability to stim- 
ulate chemotaxis. Whether or not synergism exists 
between haptotactic stimuli and PDGF may also 
be relevant and will be the focus of future investi- 
gations. 
Migration of medial SMCs to the neointima is a 
critical component in the pathophysiolic mechanism 
of restenosis after arterial injury, and inhibition of 
this process could have important impact on improv- 
ing long-term patency rates of vascular econstruc- 
tions. Understanding the relevant agonists of migra- 
tion, their relative potency, and their combined 
effects is a prerequisite o designing effective inhibi- 
tors of this process. Injury to the vessel wall that 
results from vascular econstruction creates an envi- 
ronment in which SMCs are simultaneously exposed 
to a plethora of stimuli that can promote the hyper- 
plastic response. We have made the physiologic ob- 
servation that stimulation of SMCs with multiple 
factors can produce an overall response that is greater 
than that produced by any individual factor. Specifi- 
cally, ECM proteins can augment the already potent 
migratory effects of PDGF. We then wished to gain 
an understanding of the underlying mechanism that 
produced this cellular esponse. We have shown that 
alterations in [Ca2+]i may be, at least in part, the 
mechanism for this synergistic effect between PDGF 
and the ECM. 
Understanding this synergy and its underlying 
mechanism is important because it potentially allows 
the identification of sites for which there is conver- 
gence of the signaling pathways of various agonists of 
intimal hyperplasia. Inhibitors designed to target 
these specific sites could prove to be far more effec- 
tive in controlling intimal hyperplasia than agents 
that inhibit only the individual agonists of SMC 
migration. 
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